ID   A2780veliR
AC   CVCL_C1NE
DR   cancercelllines; CVCL_C1NE
DR   Wikidata; Q114310504
RX   PubMed=34445211;
CC   Population: African American.
CC   Selected for resistance to: ChEBI; CHEBI:62880; Veliparib (ABT-888).
CC   Sequence variation: Mutation; HGNC; 795; ATM; Simple; p.Pro604Ser (c.1810C>T); ClinVar=VCV000127343; Zygosity=Unspecified (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Lys128_Arg130del (c.383_391del9); Zygosity=Unspecified (from parent cell line).
CC   Derived from site: In situ; Ovary; UBERON=UBERON_0000992.
DI   NCIt; C7979; Ovarian endometrioid adenocarcinoma
DI   ORDO; Orphanet_454723; Endometrioid carcinoma of ovary
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_0134 ! A2780
SX   Female
AG   Age unspecified
CA   Cancer cell line
DT   Created: 22-09-22; Last updated: 05-10-23; Version: 5
//
RX   PubMed=34445211; DOI=10.3390/ijms22168506;
RA   Dickson K.-A., Xie T., Evenhuis C., Ma Y., Marsh D.J.;
RT   "PARP inhibitors display differential efficacy in models of BRCA
RT   mutant high-grade serous ovarian cancer.";
RL   Int. J. Mol. Sci. 22:8506.1-8506.14(2021).
//